Publications

2021

  1. Maxwell MJ, Arnold A, Sweeney H, Chen L, Lih TM, Schnaubelt M, Eberhart CG, Rubens JA, Zhang H, Clark DJ, Raabe EH. Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant glioma. Mol Cell Proteomics. 2021 Jul 20:100123. Online ahead of print.
  2. Yuan M, White D, Resar L, Bar E, Groves M, Cohen A, Jackson E, Bynum J, Rubens J, Mumm J, Chen L, Jiang L, Raabe E, Rodriguez FJ, Eberhart CG. Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. Neuro Oncol. 2021 May 5;23(5):770-782.
  3. Nakata S, Yuan M, Rubens JA, Kahlert UD, Maciaczyk J, Raabe EH, Eberhart CG. BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion, and Expression of PRC2 Targets. Int J Mol Sci. 2021 Apr 10;22(8):3913.
  4. Pham K, Maxwell MJ, Sweeney H, Alt J, Rais R, Eberhart CG, Slusher BS, Raabe EH. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis. J Neuropathol Exp Neurol. 2021 Mar 22;80(4):336-344.

2020

  1. Shahab S, Rubens J, Kaur H, Sweeney H, Eberhart CG, Raabe EH. MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. J Neuropathol Exp Neurol. 2020 Jul 1;79(7):746-753.
  2. Arnold A, Yuan M, Price A, Harris L, Eberhart CG, Raabe EH. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity. Neuro Oncol. 2020 Apr 15;22(4):563-574.
  3. Martin AM, Bell WR, Yuan M, Harris L, Poore B, Arnold A, Engle EL, Asnaghi L, Lim M, Raabe EH, Eberhart CG. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. J Neuropathol Exp Neurol. 2020 Jan 1;79(1):74-85.

2019

  1. Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, Kaur H, Orr BA, Slusher BS, Eberhart CG, Raabe EH, Rubens JA. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clin Cancer Res. 2019 Oct 1;25(19):5925-5936.
  2. Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019  Oct;12(10):1314-1322.
  3. Yuan M, Da Silva ACAL, Arnold A, Okeke L, Ames H, Correa-Cerro LS, Vizcaino MA, Ho CY, Eberhart CG, Rodriguez FJ. MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep. 2018 Aug 21; (1):12506.
  4. Natsumeda M, Liu Y, Nakata S, Miyahara H, Hanaford A, Ahsan S, Stearns D, Skuli N, Kahlert UD, Raabe EH, Rodriguez FJ, Eberhart CG. Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma. Neuropathology. 2019 Apr;39(2):71-77.
  5. Asnaghi L, White DT, Key N, Choi J, Mahale A, Alkatan H, Edward DP, Elkhamary SM, Al-Mesfer S, Maktabi A, Hurtado CG, Lee GY, Carcaboso AM, Mumm JS, Safieh LA, Eberhart CG. ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene. 2019 Mar;38(12):2056-2075.
  6. Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens JA, Slusher BS, Eberhart CG, Raabe EH. mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro Oncol. 2019 Feb 14;21(2):252-263.

 

 

2018

  1. Ames HM, Rooper LM, Laterra JJ, Eberhart CG, Rodriguez FJ. J INSM1 Expression Is Frequent in Primary Central Nervous System Neoplasms but Not in the Adult Brain Parenchyma. Neuropathol Exp Neurol. 2018; 77(5):374-382.
  2. Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M. PD-L1 expression in medulloblastoma: an evaluation by subgroup.Oncotarget 2018;9 (27):19177-19191.
  3. Qin H, Moore RF, Ho CY, Eshleman J, Eberhart CG*, Cuda J. Endocrine mucin-producing sweat gland carcinoma: A study of eleven cases with molecular analysis. J Cutan Pathol. 2018 Jun 25 (Epub Ahead of print). PMID: 29943394. (*corresponding author)

2017

  1. Semenkow S, Li S, Kahlert UD, Raabe EH, Xu J, Arnold A, Janowski M, Oh BC, Brandacher G, Bulte JWM, Eberhart CG* and Walczak P. An immunocompetent mouse model of human glioblastoma. Oncotarget 2017; 8(37):61072-61082. (*corresponding author)
  2. Rubens JA, Wang SZ, Price A, Weingart MF, Allen SJ, Orr BA, Eberhart CG, Raabe EH. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro Oncol. 2017 19(10):1361-1371.
  3. Yang Q, Tripathy A, Yu W, Eberhart CG*, Asnaghi L. Hypoxia inhibits growth, proliferation, and increases response to chemotherapy in retinoblastoma cells. Exp Eye Res. 2017; 162:48-61.
  4. Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017 Aug 1;400:110-116.

2016

  1. Kahlert UD, Cheng M, Koch K, Marchionni L, Fan X, Raabe EH, Maciaczyk J, Glunde K, Eberhart CG. Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells. Int J Cancer. 2016 Mar 1;138(5):1246-55.
  2. Bell WR, Singh K, Rajan Kd A, Eberhart CG. Expression of p16 and p53 in Intraepithelial Periocular Sebaceous Carcinoma. Ocul Oncol Pathol. 2015 Dec;2(2):71-5.
  3. Kaur H, Ali SZ, Huey L, Hütt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10;377(1):55-64.
  4. Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dančík V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees MG, Shamji A, Schreiber S, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG, Raabe EH. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016 Aug 1;22(15):3903-14.
  5. Mahale A, Alkatan H, Alwadani S, Othman M, Suarez MJ, Price A, Al-Hussain H, Jastaneiah S, Yu W, Maktabi A, Deepak EP, Eberhart CG, Asnaghi L. Altered gene expression in conjunctival squamous cell carcinoma. Mod Pathol. 2016 May;29(5):452-60.
  6. Rodriguez FJ, Vizcaino MA, Blakeley J, Heaphy CM. Frequent alternative lengthening of    telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas. Acta Neuropathol. 2016 Sep 20.
  7. Suarez MJ, Rivera-Michlig R, Dubovy S, Rodriguez FJ. Clinicopathological Features of Ophthalmic Neoplasms Arising in the Setting of Xeroderma Pigmentosum. Ocul Oncol Pathol. 2015 Dec;2(2):112-21.
  8. Vizcaíno MA, Bishop J, Sharma R, Refaey K, Quiñones-Hinojosa A, Rodriguez FJ. Intracranial solitary fibrous tumor/ hemangiopericytoma with osteoclast-like multinucleated giant cells: comparison with giant cell-rich solitary fibrous tumor. Clin Neuropathol. 2016 Jul-Aug;35(4):171-7.
  9. Asnaghi L, Tripathy A, Yang Q, Kaur H, Hanaford A, Yu W, Eberhart CG. Targeting Notch signaling as a novel therapy for retinoblastoma. Oncotarget. 2016 Sep 20.

2015

  1. Lim KJ, Brandt WD, Heth JA, Muraszko KM, Fan X, Bar EE, Eberhart CG. Lateral inhibition of Notch signaling in neoplastic cells. Oncotarget. 2015 Jan 30;6(3):1666-77.
  2. Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Notch signaling activation in pediatric low-grade astrocytoma. J Neuropathol Exp Neurol. 2015 Feb;74(2):121-31.
  3. Kaur H, Hütt-Cabezas M, Weingart MF, Xu J, Kuwahara Y, Erdreich-Epstein A, Weissman BE, Eberhart CG, Raabe EH. The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity. J Neuropathol Exp Neurol. 2015 Feb;74(2):177-85.
  4. Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, Orr BA, Eberhart CG, Biegel JA, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 2015 Feb 20;6(5):3165-77.
  5. Taylor IC, Hütt-Cabezas M, Brandt WD, Kambhampati M, Nazarian J, Chang HT, Warren KE, Eberhart CG, Raabe EH. Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition. J Neuropathol Exp Neurol. 2015 Aug;74(8):778-90.
  6. Vizcaíno MA, Shah S, Eberhart CG, Rodriguez FJ. Clinicopathologic implications of NF1 gene alterations in diffuse gliomas. Hum Pathol. 2015 Sep;46(9):1323-30. doi: 10.1016/j.humpath.2015.05.014
  7. Kahlert UD, Suwala AK, Koch K, Natsumeda M, Orr BA, Hayashi M, Maciaczyk J, Eberhart CG. Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. J Neuropathol Exp Neurol. 2015 Sep;74(9):889-900.
  8. Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG. EMT-associated factors promote invasive properties of uveal melanoma cells. Mol Vis. 2015 Aug 25;21:919-29.
  9. Natsumeda M, Maitani K, Liu Y, Miyahara H, Kaur H, Chu Q, Zhang H, Kahlert U, Eberhart CG. Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. Brain Pathol. 2015 Nov 27.
  10. Ho CY, Mosier S, Safneck J, Salomao DR, Miller NR, Eberhart CG, Gocke CD, Batista DA, Rodriguez FJ. Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma. Brain Pathol. 2015 Mar;25(2):193-201.
  11. Nauen D, Haley L, Lin MT, Perry A, Giannini C, Burger PC, Rodriguez FJ. Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. Brain Pathol. 2015 Jul 23.
  12. Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, Esbenshade AJ, Tehrani M, Orr BA, LaFrance DR, Devaney JM, Meltzer BW, Hofherr SE, Burger PC, Packer RJ, Rodriguez FJ. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathol. 2015 Oct;130(4):575-85.
  13. Rodriguez, FJ; Schniederjan, MJ; Nicolaides, T; Tihan, T; Burger, PC; Perry, A. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol., 2015 vol. 129(4) pp. 609-10.

2014

  1. AlWadani S, Robinson S, Myers R, Akpek EK, Eberhart CG. No increase in IgG4-positive plasma cells in limbal Rosai-Dorfman disease. Cornea. 2014 Aug;33(8):844-7.
  2. Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, Ballester LY, Nazarian J, Eberhart CG, Rodriguez FJ. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2014 Jun 3;2:59.
  3. Rajaii F, Asnaghi L, Enke R, Merbs SL, Handa JT, Eberhart CG. The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma. Invest Ophthalmol Vis Sci. 2014 Aug 21;55(10):6178-86.
  4. Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, Merbs SL, Handa JT, Sodhi A, Bar EE, Eberhart CG. Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation. PLoS One. 2014 Aug 28;9(8):e105372.
  5. Asnaghi L, Alkatan H, Mahale A, Othman M, Alwadani S, Al-Hussain H, Jastaneiah S, Yu W, Maktabi A, Edward DP, Eberhart CG. Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma. Invest Ophthalmol Vis Sci. 2014 Dec 9;55(12):8604-13.
  6. Ding D, Lim Ks, Eberhart CG.  Arsenic trioxide inhibits hedgehog, notch and stem cell properties in glioblastoma neurospheres.  Acta Neuropathol Commun 2014;31;2(1):31.
  7. Rajan A, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG.  DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.  Am J Ophthalmol 2014;157:640-7.
  8. Kahlert UD, Suwala AK, Raabe EH, Siebzehnrubi FA, Suarez MJ, Orr BA, Bar EE, Maciaczyk J, Eberhart CG.  ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres.  Brain Pathol 2014 Dec 17.

2013

  1. Mao XG, Hütt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG, Raabe EH. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget. 2013 Jul;4(7):1050-64.
  2. Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ. . cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. J Neurooncol. 2013 Nov;115(2):249-59.
  3. Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathol. 2013 Oct;126(4):607-8.
  4. Lim KS, Lim KJ, Price AC, Orr BA, Eberhart CG, Bar EE. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene. 2014 Aug 28;33(35):4433-41.
  5. Hütt-Cabezas M, Karajannis MA, Zagzag D, Shah S, Horkayne-Szakaly I, Rushing EJ, Cameron JD, Jain D, Eberhart CG, Raabe EH, Rodriguez FJ. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro Oncol. 2013 Dec;15(12):1604-14.
  6. Rajan Kd A, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol. 2014 Mar;157(3):640-7.e1-2. doi: 10.1016/j.ajo.2013.12.002.
  7. Codispoti KE, Mosier S, Ramsey R, Lin MT, Rodriguez FJ. Genetic and pathologic evolution of early secondary gliosarcoma. Brain Tumor Pathol. 2014 Jan;31(1):40-6. doi: 10.1007/s10014-012-0132-y.
  8. Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ.  Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas.  Brain Pathol 2013;23(3):237-43.
  9. Chu Q, Orr BA, Semenkow S, Bar EE, Eberhart CG.  Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade. Clin Cancer Res 2013;19(12):3224-33.
  10. Asnaghi L, Handa JT, Merbs SL, Harbour JW, Eberhart CG.  A role for Jag2 in promoting uveal melanoma dissemination and growth. Invest Ophthalmol Vis Sci 2013;54(1):295-306.

2012

  1. Lim KJ, Rajan K, Eberhart CG. Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling. Anticancer Res. 2012 Jul;32(7):2689-96.
  2. Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One. 2012;7(7):e41036
  3. Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, Rushing EJ, Ligon KL, Vena N, Garcia DI, Cameron JD, Eberhart CG. BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol. 2012 Sep;71(9):789-94.
  4. Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol. 2013 May;23(3):237-43.
  5. Raabe EH, Eberhart CG. Methylome alterations “mark” new therapeutic opportunities in glioblastoma. Cancer Cell. 2012 Oct 16;22(4):417-8.
  6. Rodriguez FJ, Lim KS, Bowers D, Eberhart CG. Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol. 2013 Jan 24;8:361-79.
  7. Ho CY, Bar E, Giannini C, Marchionni L, Karajannis MA, Zagzag D, Gutmann DH, Eberhart CG, Rodriguez FJ. MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol. 2013 Jan;15(1):69-82.
  8. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, Burger PC, Allen JC, Eberhart CG, Bar EE. BRAF Alterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549: BRAF Fusion Variants. J Neuropathol Exp Neurol 2012;71:66-72.
  9. Rodriguez FJ, Orr BA, Ligon KL, Eberhart CG.  Neoplastic cells are a rare component in human glioblastoma microvasculature.  Oncotarget 2012;3:98-106.
  10. Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG.  Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res 2012;18(3):654-65.
  11. Rodriguez FJ, Perry A, Rosenblum MK, Krawitz S, Cohen KJ, Lin D, Mosier S, Lin MT, Eberhart CG, Burger PC. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol 2012;124(5):627-41.

2011

  1. Pierfelice TJ, Schreck KC, Dang L, Asnaghi L, Gaiano N, Eberhart CG. Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res. 2011 Feb 1;71(3):1115-25.
  2. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res. 2011 Jun 1;17(11):3590-9.
  3. Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol. 2011 Jul;70(7):568-77.
  4. Karafin M, Jallo GI, Ayars M, Eberhart CG, Rodriguez FJ. Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications. Clin Neuropathol. 2011 Nov-Dec;30(6):297-300.
  5. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG.  A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors.  Cancer Biol Ther 2011

2010

  1. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG. NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts. Stem Cells. 2010, 28(1):5-16.
  2. Bar EE, Lin A, Mahairaki V, Matsui W, and Eberhart CG. Hypoxia Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in Glioblastoma Neurospheres. Am J Pathol 2010, 177(3):1491-502.
  3. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, Eberhart CG.  The notch target hes1 directly modulates gli1 expression and hedgehog signaling:  a potential mechanism of therapeutic resistance.  Clin Cancer Res 2010:16(24):6060-70.

2008

  1. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008, 67:878-87.
  2. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol. 2008, 26:2821-7.

2007

  1. E Bar, A Chaudhry, CG Eberhart. Hedgehog Signaling Promotes Medulloblastoma Survival via Bcl2. American Journal of Pathology 2007, 170:347-55.
  2. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Vescovi AL, Piccirillo S, Dimeco F, Olivi A, Eberhart CG. Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. Stem Cells. 2007, 25:2524-33.

2006

  1. Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, and CG Eberhart. Notch3 Signaling Initiates Choroid Plexus Tumor Formation. Oncogene 2006, 25:487-91.
  2. D Stearns, A Chaudhry, T Abel, PC. Burger, CV. Dang, CG Eberhart. c-Myc Overexpression Causes Anaplasia in Medulloblastoma. Cancer Res. 2006, 66:673-81.
  3. X Fan, W Matsui, L Khaki, D Stearns, J Chun, YM Li, CG Eberhart. Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors. Cancer Research 2006 66:7445-52.

2005

  1. TW Abel, SJ Baker, MM Fraser, T Tihan, JS Nelson, A Yachnis, J Bouffard, H Mena, PC Burger, CG Eberhart. Lhermitte-Duclos Disease: a Report of 31 Cases with Immunohistochemical Analysis of the PTEN/AKT/mTOR Pathway. J Neuropath Exp Neurol. 2005, 64:1-9.

2004

  1. X Fan, I Mikolaenko, I Elhassan, XZ Ni, Y Wang, D Ball, DJ Brat, A Perry, and CG. Eberhart. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004, 64(21):7787-93

2003

  1. X Fan, Y Wang, J Kratz, DJ Brat, Y Robitaille, A Moghrabi, EJ Perlman, CV.  Dang, PC Burger, CG Eberhart. hTERT Gene Amplification and Increased mRNA Expression in CNS Embryonal Tumors. Am J Pathol 2003, 162(6):1763-9.

2002

  1. JE. Kratz, D Stearns, DL Huso, HH Slunt, DL Price, DR Borchelt, CG Eberhart. Expression of stabilized beta-catenin in the CNS of adult transgenic mice does not result in tumor formation. BMC Cancer 2002, 2:33.